Listed in the Appendix.
Stroke. 2022 Mar;53(3):956-967. doi: 10.1161/STROKEAHA.121.035216. Epub 2021 Dec 1.
Optimizing speech and language therapy (SLT) regimens for maximal aphasia recovery is a clinical research priority. We examined associations between SLT intensity (hours/week), dosage (total hours), frequency (days/week), duration (weeks), delivery (face to face, computer supported, individual tailoring, and home practice), content, and language outcomes for people with aphasia.
Databases including MEDLINE and Embase were searched (inception to September 2015). Published, unpublished, and emerging trials including SLT and ≥10 individual participant data on aphasia, language outcomes, and time post-onset were selected. Patient-level data on stroke, language, SLT, and trial risk of bias were independently extracted. Outcome measurement scores were standardized. A statistical inferencing, one-stage, random effects, network meta-analysis approach filtered individual participant data into an optimal model examining SLT regimen for overall language, auditory comprehension, naming, and functional communication pre-post intervention gains, adjusting for a priori-defined covariates (age, sex, time poststroke, and baseline aphasia severity), reporting estimates of mean change scores (95% CI).
Data from 959 individual participant data (25 trials) were included. Greatest gains in overall language and comprehension were associated with >20 to 50 hours SLT dosage (18.37 [10.58-26.16] Western Aphasia Battery-Aphasia Quotient; 5.23 [1.51-8.95] Aachen Aphasia Test-Token Test). Greatest clinical overall language, functional communication, and comprehension gains were associated with 2 to 4 and 9+ SLT hours/week. Greatest clinical gains were associated with frequent SLT for overall language, functional communication (3-5+ days/week), and comprehension (4-5 days/week). Evidence of comprehension gains was absent for SLT ≤20 hours, <3 hours/week, and ≤3 days/week. Mixed receptive-expressive therapy, functionally tailored, with prescribed home practice was associated with the greatest overall gains. Relative variance was <30%. Risk of trial bias was low to moderate; low for meta-biases.
Greatest language recovery was associated with frequent, functionally tailored, receptive-expressive SLT, with prescribed home practice at a greater intensity and duration than reports of usual clinical services internationally. These exploratory findings suggest critical therapeutic ranges, informing hypothesis-testing trials and tailoring of clinical services. Registration: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42018110947.
优化言语和语言治疗(SLT)方案以实现最大的失语症康复是临床研究的重点。我们研究了失语症患者的 SLT 强度(每周小时数)、剂量(总小时数)、频率(每周天数)、持续时间(周数)、传递方式(面对面、计算机支持、个体化定制和家庭练习)与语言结果之间的关联。
检索了包括 MEDLINE 和 Embase 在内的数据库(从开始到 2015 年 9 月)。选择了发表的、未发表的和正在进行的试验,包括 SLT 和≥10 名个体参与者的数据,涉及失语症、语言结果和发病后时间。独立提取了患者的卒中、语言、SLT 和试验偏倚风险的数据。对结局测量评分进行了标准化。采用统计推断、单阶段、随机效应、网络荟萃分析方法,将个体参与者数据过滤到最佳模型中,以研究干预前后整体语言、听觉理解、命名和功能交流的 SLT 方案,调整了预先定义的协变量(年龄、性别、卒中后时间和基线失语症严重程度),报告平均变化分数的估计值(95%CI)。
纳入了 959 名个体参与者数据(25 项试验)。在 SLT 剂量超过 20 至 50 小时时,整体语言和理解能力的提高最大(25.37[10.58-26.16]Western Aphasia Battery-Aphasia Quotient;5.23[1.51-8.95]Aachen Aphasia Test-Token Test)。在 SLT 每周 2 至 4 小时和 9 小时以上时,最大的临床整体语言、功能交流和理解能力的提高与 SLT 相关。最频繁的 SLT 与整体语言、功能交流(3-5 天/周)和理解(4-5 天/周)相关。在 SLT 每周≤20 小时、每周<3 小时和每周≤3 天时,无理解能力提高的证据。混合接受性表达疗法、功能定制,加上规定的家庭练习与最大的整体获益相关。相对方差<30%。试验偏倚风险为低到中度;meta 偏倚风险低。
最显著的语言恢复与频繁、功能定制、接受性表达的 SLT 相关,且与国际上常规临床服务报告的强度和持续时间相比,家庭练习的规定更为严格。这些探索性发现提示了重要的治疗范围,为假设检验试验和临床服务的定制提供了信息。注册:网址:https://www.crd.york.ac.uk/PROSPERO/;唯一标识符:CRD42018110947。